{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:46:29Z","timestamp":1783637189128,"version":"3.55.0"},"reference-count":108,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Major depression is a debilitating, sometimes fatal disorder, deteriorating\nthe quality of life and well-being. Escitalopram showed highly selective and dose-dependent inhibitory\nactivity on human serotonin transport. Selective serotonin reuptake inhibitors (SSRIs) are the\nfirst-line drugs to manage major depressive disorder (MDD).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The objective of this study is to explore the therapeutic potential of escitalopram, a clinically\napproved drug to manage MDD and panic disorders.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>It emphasizes comparative and clinical trial studies with several pharmacological targets\nreviewed from the data available on PubMed, Science Direct, Clinicaltrails.gov, and from many\nreputed foundations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result:<\/jats:title>\n<jats:p>To highlight the clinical efficacy, safety, recent development, and stable formulation of\nescitalopram with an increased bioavailability profile. Evidence-based on the available clinical and\npharmacoeconomic data, escitalopram represents an effective first-line treatment option for MDD\npatients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The present review highlights the placebo-controlled clinical studies and the recent\ndevelopment that can be helpful for further research perspectives.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527321666220301122807","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T07:15:45Z","timestamp":1646205345000},"page":"41-50","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Review of Clinical Studies Assessing the Therapeutic Efficacy of\nEscitalopram: A Step Towards Development"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7574-2971","authenticated-orcid":true,"given":"Ashwani K.","family":"Dhingra","sequence":"first","affiliation":[{"name":"Guru Gobind Singh College of Pharmacy, City Center Road, Yamuna Nagar-135001, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Guru Gobind Singh College of Pharmacy, City Center Road, Yamuna Nagar-135001, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawna","family":"Chopra","sequence":"additional","affiliation":[{"name":"Guru Gobind Singh College of Pharmacy, City Center Road, Yamuna Nagar-135001, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Guarve","sequence":"additional","affiliation":[{"name":"Guru Gobind Singh College of Pharmacy, City Center Road, Yamuna Nagar-135001, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00023210-200317050-00004","volume":"17","author":"Waugh J.","year":"2003","unstructured":"Waugh J.; Goa K.L.; Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003,17(5),343-362","journal-title":"CNS Drugs"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","volume":"167","author":"S&#xE1;nchez C.","year":"2003","unstructured":"S&#xE1;nchez C.; Bergqvist P.B.; Brennum L.T.; Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003,167(4),353-362","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.euroneuro.2004.08.008","volume":"15","author":"Chen F.","year":"2005","unstructured":"Chen F.; Larsen M.B.; S&#xE1;nchez C.; Wiborg O.; The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005,15(2),193-198","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0028-3908(03)00138-2","volume":"45","author":"M&#xF8;rk A.","year":"2003","unstructured":"M&#xF8;rk A.; Kreilgaard M.; S&#xE1;nchez C.; The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003,45(2),167-173","journal-title":"Neuropharmacology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/sj.npp.1300686","volume":"30","author":"El Mansari M.","year":"2005","unstructured":"El Mansari M.; S&#xE1;nchez C.; Chouvet G.; Renaud B.; Haddjeri N.; Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: An in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005,30(7),1269-1277","journal-title":"Neuropsychopharmacology"},{"key":"ref=6","first-page":"371","volume":"48","author":"Kimura M.","year":"2012","unstructured":"Kimura M.; Escitalopram oxalate. J Jpn Soc Hosp Pharm 2012,48,371-375","journal-title":"J Jpn Soc Hosp Pharm"},{"key":"ref=7","author":"Kleemann A.","year":"2014","unstructured":"Kleemann A.; Anti-depressants. Ullmann\u2019s Encyclopedia of Industrial Chemistry 2014","journal-title":"Ullmann\u2019s Encyclopedia of Industrial Chemistry"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.2165\/00003495-200565160-00013","volume":"65","author":"Murdoch D.","year":"2005","unstructured":"Murdoch D.; Keam S.J.; Escitalopram: A review of its use in the management of major depressive disorder. Drugs 2005,65(16),2379-2404","journal-title":"Drugs"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0006-3223(01)01145-3","volume":"50","author":"Owens M.J.","year":"2001","unstructured":"Owens M.J.; Knight D.L.; Nemeroff C.B.; Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001,50(5),345-350","journal-title":"Biol Psychiatry"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2165\/00023210-200620090-00010","volume":"20","author":"Dhillon S.","year":"2006","unstructured":"Dhillon S.; Scott L.J.; Plosker G.L.; Escitalopram: A review of its use in the management of anxiety disorders. CNS Drugs 2006,20(9),763-790","journal-title":"CNS Drugs"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1471-4159.2004.02835.x","volume":"92","author":"Chen F.","year":"2005","unstructured":"Chen F.; Larsen M.B.; Neubauer H.A.; S&#xE1;nchez C.; Plenge P.; Wiborg O.; Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 2005,92(1),21-28","journal-title":"J Neurochem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1124\/mol.105.018507","volume":"69","author":"Neubauer H.A.","year":"2006","unstructured":"Neubauer H.A.; Hansen C.G.; Wiborg O.; Dissection of an allosteric mechanism on the serotonin transporter: A cross-species study. Mol Pharmacol 2006,69(4),1242-1250","journal-title":"Mol Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00213-004-1865-z","volume":"174","author":"S&#xE1;nchez C.","year":"2004","unstructured":"S&#xE1;nchez C.; B&#xF8;ges&#xF8; K.P.; Ebert B.; Reines E.H.; Braestrup C.; Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004,174(2),163-176","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00213-006-0666-y","volume":"191","author":"Klein N.","year":"2007","unstructured":"Klein N.; Sacher J.; Geiss-Granadia T.; Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: An [123I]ADAM SPECT study. Psychopharmacology (Berl) 2007,191(2),333-339","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"Spina E.","year":"2008","unstructured":"Spina E.; Santoro V.; D\u2019Arrigo C.; Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008,30(7),1206-1227","journal-title":"Clin Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00004850-200205000-00001","volume":"17","author":"Wade A.","year":"2002","unstructured":"Wade A.; Michael L.O.; Bang H.K.; Escitalopram 10 mg\/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002,17(3),95-102","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4088\/JCP.v63n0410","volume":"63","author":"Burke W.J.","year":"2002","unstructured":"Burke W.J.; Gergel I.; Bose A.; Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002,63(4),331-336","journal-title":"J Clin Psychiatry"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.yic.0000074988.54339.7c","volume":"18","author":"Lepola U.M.","year":"2003","unstructured":"Lepola U.M.; Loft H.; Reines E.H.; Escitalopram (10-20 mg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003,18(4),211-217","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=19","first-page":"333","volume":"46","author":"Lalit V.","year":"2004","unstructured":"Lalit V.; Appaya P.M.; Hegde R.P.; Escitalopram versus citalopram and sertraline: A double-blind controlled, multi-centric trial in Indian patients with unipolar major depression. Indian J Psychiatry 2004,46(4),333-341","journal-title":"Indian J Psychiatry"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00004850-200505000-00002","volume":"20","author":"Moore N.","year":"2005","unstructured":"Moore N.; Verdoux H.; Fantino B.; Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005,20(3),131-137","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00213-010-1822-y","volume":"213","author":"Ou J.J.","year":"2011","unstructured":"Ou J.J.; Xun G.L.; Wu R.R.; Efficacy and safety of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology (Berl) 2011,213(2-3),639-646","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.clinthera.2007.11.014","volume":"29","author":"Yevtushenko V.Y.","year":"2007","unstructured":"Yevtushenko V.Y.; Belous A.I.; Yevtushenko Y.G.; Gusinin S.E.; Buzik O.J.; Agibalova T.V.; Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007,29(11),2319-2332","journal-title":"Clin Ther"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1017\/S146114571000115X","volume":"14","author":"Montgomery S.","year":"2011","unstructured":"Montgomery S.; Hansen T.; Kasper S.; Efficacy of escitalopram compared to citalopram: A meta-analysis. Int J Neuropsychopharmacol 2011,14(2),261-268","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3325\/cmj.2010.51.61","volume":"51","author":"Trkulja V.","year":"2010","unstructured":"Trkulja V.; Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat Med J 2010,51(1),61-73","journal-title":"Croat Med J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1185\/030079906X115513","volume":"22","author":"Boulenger J.P.","year":"2006","unstructured":"Boulenger J.P.; Huusom A.K.; Florea I.; Baekdal T.; Sarchiapone M.; A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006,22(7),1331-1341","journal-title":"Curr Med Res Opin"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/01.yic.0000194377.88330.1d","volume":"21","author":"Baldwin D.S.","year":"2006","unstructured":"Baldwin D.S.; Cooper J.A.; Huusom A.K.; Hindmarch I.; A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006,21(3),159-169","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=27","first-page":"883","volume":"14","author":"Hirayasu Y.","year":"2011","unstructured":"Hirayasu Y.; A dose-response and non-inferiority study evaluating the efficacy and safety of escitalopram in patients with major depressive disorder: A placebo- and paroxetine-controlled, double-blind, comparative study. Jpn J Clin Psychopharmacol 2011,14,883-899","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/da.20222","volume":"25","author":"Mao P.X.","year":"2008","unstructured":"Mao P.X.; Tang Y.L.; Jiang F.; Escitalopram in major depressive disorder: A multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress Anxiety 2008,25(1),46-54","journal-title":"Depress Anxiety"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1185\/030079906X167273","volume":"23","author":"Ventura D.","year":"2007","unstructured":"Ventura D.; Armstrong E.P.; Skrepnek G.H.; Haim Erder M.; Escitalopram versus sertraline in the treatment of major depressive disorder: A randomized clinical trial. Curr Med Res Opin 2007,23(2),245-250","journal-title":"Curr Med Res Opin"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00044011-200727070-00005","volume":"27","author":"Khan A.","year":"2007","unstructured":"Khan A.; Bose A.; Alexopoulos G.S.; Gommoll C.; Li D.; Gandhi C.; Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007,27(7),481-492","journal-title":"Clin Drug Investig"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1185\/030079907X210732","volume":"23","author":"Wade A.","year":"2007","unstructured":"Wade A.; Gembert K.; Florea I.; A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007,23(7),1605-1614","journal-title":"Curr Med Res Opin"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.4088\/JCP.v65n0906","volume":"65","author":"Bielski R.J.","year":"2004","unstructured":"Bielski R.J.; Ventura D.; Chang C.C.; A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004,65(9),1190-1196","journal-title":"J Clin Psychiatry"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000078225","volume":"50","author":"Montgomery S.A.","year":"2004","unstructured":"Montgomery S.A.; Huusom A.K.; Bothmer J.; A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004,50(1),57-64","journal-title":"Neuropsychobiology"},{"key":"ref=34","first-page":"901","volume":"14","author":"Hirayasu Y.","year":"2011","unstructured":"Hirayasu Y.; A long-term administration study of escitalopram in patients with major depressive disorders. Jpn J Clin Psychopharmacol 2011,14,901-912","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/01.JGP.0000240823.94522.4c","volume":"15","author":"Gorwood P.","year":"2007","unstructured":"Gorwood P.; Weiller E.; Lemming O.; Katona C.; Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007,15(7),581-593","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.4088\/JCP.v67n1115","volume":"67","author":"Kornstein S.G.","year":"2006","unstructured":"Kornstein S.G.; Bose A.; Li D.; Saikali K.G.; Gandhi C.; Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006,67(11),1767-1775","journal-title":"J Clin Psychiatry"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1185\/03007990802622726","volume":"25","author":"Kennedy S.H.","year":"2009","unstructured":"Kennedy S.H.; Andersen H.F.; Thase M.E.; Escitalopram in the treatment of major depressive disorder: A meta-analysis. Curr Med Res Opin 2009,25(1),161-175","journal-title":"Curr Med Res Opin"},{"key":"ref=38","unstructured":"Serotonin transporter inhibitor escitalopram in pulmonary hypertension. Assistance Publique - Hopitaux de ParisAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=39","author":"Lundbeck H.","unstructured":"Lundbeck H.; Escitalopram in patients with social anxiety disorder. Available from:   (Accessed: August 5, 2021)."},{"key":"ref=40","author":"Lundbeck H.","unstructured":"Lundbeck H.; Escitalopram in patients with generalized anxiety disorder. Available from:   (Accessed: August 5, 2021)."},{"key":"ref=41","unstructured":"Investigation of a combination treatment of escitalopram and rTMS Charite University, Berlin, Germany.Available from:   (Accessed: August 5, 2021)."},{"key":"ref=42","unstructured":"Comparison of effects between conventional dose and high dose escitalopram on clinical improvement in patients with obsessive-compulsive disorder. Seoul National University HospitalAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=43","unstructured":"Escitalopram in the treatment of postpartum depression. BC Women\u2019s Hospital"},{"key":"ref=44","unstructured":"Escitalopram treatment of patients with agitated dementia. University of RochesterAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=45","unstructured":"Study of Escitalopram in adult patients with major depressive disorder. Forest LaboratoriesAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=46","unstructured":"Comparison of escitalopram combination in adult patients with major depressive disorder. Forest LaboratoriesAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=47","unstructured":"MOTIV Study- effect of antidepressive treatment by escitalopram in patients undergoing coronary artery bypass grafting Hopital Jean MinjozAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=48","unstructured":"Escitalopram combination comparison study for adult patients with major depressive disorder. Pharmacology Research InstituteAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=49","unstructured":"The effects of escitalopram on cytokines (BAFH) Beitou Armed Forces HospitalAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=50","unstructured":"Modafinil - escitalopram study for cocaine dependence Baylor College of MedicineAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=51","unstructured":"Neuroprotective\/neurotrophic effect of lexapro&#xAE; in patients with posttraumatic stress disorder. Seoul National University HospitalAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=52","unstructured":"A PET study to determine alterations in serotonin levels in human brain after a single dose of escitalopram. Karolinska InstitutetAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=53","unstructured":"Eszopiclone co-administered with escitalopram for insomnia in elderly adults with major depressive disorder. Lehigh Center for Clinical ResearchAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=54","author":"Lundbeck H.","unstructured":"Lundbeck H.; Bioequivalence study comparing two formulations of escitalopram. Available from:   (Accessed: August 5, 2021)."},{"key":"ref=55","unstructured":"Comparison of tianeptine versus escitalopram patients major depressive disorder (CAMPION). Samsung Medical CenterAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=56","unstructured":"Lexapro and pramipexole and to treat major depression. National Institute of Mental Health (NIMH)Available from:   (Accessed: August 5, 2021)."},{"key":"ref=57","unstructured":"Quetiapine prolong, escitalopram and hypothalamic-pituitary-adrenocortical (HPA) axis activity in depressed patients. Ludwig-Maximilians - University of MunichAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=58","unstructured":"MsFLASH-01: Escitalopram for menopausal symptoms in midlife women.  Fred Hutchinson Cancer Research CenterAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=59","unstructured":"Escitalopram (Lexapro&#xAE;) In patients with major depression with atypical features Duke UniversityAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=60","unstructured":"Baker heart and diabetes institute. Cardiovascular effects of agomelatine and escitalopram in patients with major depressive disorder (MDD). Available from:   (Accessed: August 7, 2021)."},{"key":"ref=61","unstructured":"Xian-janssen pharmaceutical Ltd. A safety and efficacy study of escitalopram on acute treatment of severe depression. Available from:   (Accessed: August 7, 2021)."},{"key":"ref=62","unstructured":"Safety study of Escitalopram in children 7 to 11 years of age with major depressive disorder. Forest LaboratoriesAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=63","unstructured":"A clinical trial to investigate the pharmacokinetics and the effect on ECG of Escitalopram in elderly volunteers. Seoul National University HospitalAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=64","unstructured":"Massachusetts general hospital. Influence of escitalopram on fear conditioning Available from:   (Accessed: August 7, 2021)."},{"key":"ref=65","unstructured":"Escitalopram (Lexapro) for the treatment of postpartum depression (LexaproPPD) Massachusetts General HospitalAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=66","unstructured":"Treatment effects of escitalopram (lexapro&#xAE;) on generalized anxiety disorder in patients with HIV and AIDS Duke UniversityAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=67","unstructured":"The effect of patient and investigator expectation on the efficacy of Escitalopram in the treatment depression. Abarbanel Mental Health CenterAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=68","unstructured":"Development of Escitalopram genomic device by using candidate gene approach and genome-wide scanning. Samsung Medical CenterAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=69","author":"Roussy G","unstructured":"Roussy G; Campus C.; Gustave Roussy, Cancer Campus, Grand Paris. Randomized, double blind, efficacy study of escitalopram in ENT cancer patients suffering from emotional distress (TADDOR) Available from:   (Accessed: August 7, 2021)."},{"key":"ref=70","unstructured":"A Study to evaluate the impact of Escitalopram on quality of life and social functionality in patients with major depressive disorder with anxiety symptom. Xian-Janssen Pharmaceutical LtdAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=71","unstructured":"Study of brain response to emotional pictures using a magnetic resonance imaging (fMRI) while on Escitalopram Indiana University School of MedicineAvailable from:   (Accessed: August 5, 2021)."},{"key":"ref=72","unstructured":"Brain Energy Metabolism in Individuals with Major Depressive Disorder Receiving Escitalopram. Brain energy metabolism in individuals with major depressive disorder receiving Escitalopram Massachusetts General HospitalAvailable from:   (Accessed: August 7, 2021).","journal-title":"Brain energy metabolism in individuals with major depressive disorder receiving Escitalopram"},{"key":"ref=73","unstructured":"Escitalopram trial for irritable bowel syndrome (IBS) patients with panic disorder.  Maastricht University Medical CenterAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=74","unstructured":"H. Lundbeck A\/S. Efficacy of vortioxetine versus escitalopram on cognitive function in patients with inadequate response to current antidepressant treatment of major depressive disorder. Available from:   (Accessed: August 7, 2021)."},{"key":"ref=75","unstructured":"Erzurum regional training"},{"key":"ref=76","unstructured":"Bioequivalence study of Escitalopram tablets 10 mg. GlaxoSmithKlineAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=77","unstructured":"An efficacy and safety study of escitalopram long-term treatment in major depressive disorder with associated anxiety symptoms (Lexapro) Xian-Janssen Pharmaceutical LtdAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=78","unstructured":"Cognitive-behavioral therapy and escitalopram for generalized anxiety disorder (GAD) New York State Psychiatric InstituteAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=79","unstructured":"Lexapro&#xAE;'s efficacy after dose escalation in remission study (LEADERS) Seoul National University HospitalAvailable from:   (Accessed: August 7, 2021)."},{"key":"ref=80","unstructured":"Pharmacokinetic and pharmacodynamic effects of escitalopram depending on genetic polymorphisms of the ABCB1-gene. Max-Planck-Institute of PsychiatryAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=81","unstructured":"Escitalopram (Lexapro) for depression MS or ALS. University of South CarolinaAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=82","unstructured":"Effects of Escitalopram on autonomic reactivity in post traumatic stress disorder VA Nebraska Western Iowa Health Care SystemAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=83","unstructured":"Effects of Escitalopram on the sleep EEG power in patients with major depressive disorder. Peking University Sixth HospitalAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=84","unstructured":"Study to evaluate the efficacy, safety and tolerability of bupropion hydrochloride extended-release tablet, and escitalopram oxalate capsule in subjects with major depressive disorder. GlaxoSmithKlineAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=85","unstructured":"Comparative efficacy of duloxetine vs escitalopram in patients with fibromyalgia (CORTEX) Shaheed Zulfiqar Ali Bhutto Medical UniversityAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=86","unstructured":"SAT vs. Escitalopram for rectal hypersensitivity. Augusta UniversityAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=87","unstructured":"Neurofunctional predictors of escitalopram treatment response in adolescents with anxiety (FiESTAA). University of CincinnatiAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=88","unstructured":"Bupropion versus Escitalopram on reward circuitry and motivational deficits. Emory UniversityAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=89","unstructured":"Bariatric surgery and pharmacokinetics of Escitalopram. Norwegian University of Science and TechnologyAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=90","unstructured":"Impact of Escitalopram on sperm DNA fragmentation. Weill Medical College of Cornell UniversityAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=91","unstructured":"Treatments for anxiety: Meditation and Escitalopram (TAME) Georgetown UniversityAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=92","unstructured":"Pharmacogenetically-guided escitalopram treatment for pediatric anxiety: Aiming to improve safety and efficacy (PrEcISE) (PrEcISE) University of CincinnatiAvailable from:   (Accessed: August 10, 2021)."},{"key":"ref=93","unstructured":"Allergan. A Study of escitalopram in the treatment of children and adolescents with generalized anxiety disorder Available from:   (Accessed: August 10, 2021)."},{"key":"ref=94","first-page":"2462","year":"2017","unstructured":"Drug Information. American Society of Health-System Pharmacists 20172017,2462"},{"key":"ref=95","unstructured":"Current medication information for Lexapro (Escitalopram Oxalate) tablet, film coated; lexapro (Escitalopram Oxalate) solution NIH DailyMedAvailable from:   (Accessed: March 27, 2018)."},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3390\/jcm8101640","volume":"8","author":"Montejo A.L.","year":"2019","unstructured":"Montejo A.L.; Prieto N.; de Alarc&#xF3;n R.; Management strategies for antidepressant-related sexual dysfunction: A clinical approach. J Clin Med 2019,8,1640","journal-title":"J Clin Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.sxmr.2017.07.002","volume":"6","author":"Bala A.","year":"2018","unstructured":"Bala A.; Nguyen H.M.T.; Hellstrom W.J.G.; Post-SSRI sexual dysfunction: A literature review. Sex Med Rev 2018,6(1),29-34","journal-title":"Sex Med Rev"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/00926230590513474","volume":"31","author":"Ashton A.K.","year":"2005","unstructured":"Ashton A.K.; Mahmood A.; Iqbal F.; Improvements in SSRI\/SNRI-induced sexual dysfunction by switching to escitalopram. J Sex Marital Ther 2005,31(3),257-262","journal-title":"J Sex Marital Ther"},{"key":"ref=99","unstructured":"Mozarin, zamienniki i podobne produkty. Gdziepolek.plAvailable from:   (Accessed: October 17, 2020)."},{"key":"ref=100","unstructured":"international: EscitalopramAvailable from:   (Accessed: April 25, 2015)."},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2147\/PPA.S22495","volume":"6","author":"Kirino E.","year":"2012","unstructured":"Kirino E.; Escitalopram for the management of major depressive disorder: A review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence 2012,6,853-861","journal-title":"Patient Prefer Adherence"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1742-1241.2007.01335.x","volume":"61","author":"Llorca P.M.","year":"2007","unstructured":"Llorca P.M.; Fernandez J.L.; Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007,61(4),702-710","journal-title":"Int J Clin Pract"},{"key":"ref=103","first-page":"183","volume":"33","author":"Mushtaque M.","year":"2020","unstructured":"Mushtaque M.; Muhammad I.N.; Fareed H.S.M.; Ali A.; Masood R.; Development and pharmaceutical evaluation of oral fast dissolving thin film of escitalopram: A patient friendly dosage form. Pak J Pharm Sci 2020,33(1),183-189","journal-title":"Pak J Pharm Sci"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ijpharm.2017.06.089","volume":"529","author":"Wang W.","year":"2017","unstructured":"Wang W.; Song T.; Wan X.; Liu C.; Zhao H.; Fang L.; Investigate the control release effect of ion-pair in the development of escitalopram transdermal patch using FT-IR spectroscopy, molecular modeling and thermal analysis. Int J Pharm 2017,529(1-2),391-400","journal-title":"Int J Pharm"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3390\/pharmaceutics13060891","volume":"13","author":"Alkahtani M.E.","year":"2021","unstructured":"Alkahtani M.E.; Aodah A.H.; Abu A.O.A.; Basit A.W.; Orlu M.; Tawfik E.A.; Fabrication and characterization of fast-dissolving films containing escitalopram\/quetiapine for the treatment of major depressive disorder. Pharmaceutics 2021,13(6),891","journal-title":"Pharmaceutics"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s12325-010-0073-y","volume":"27","author":"Navarro V.","year":"2010","unstructured":"Navarro V.; Improving medication compliance in patients with depression: Use of orodispersible tablets. Adv Ther 2010,27(11),785-795","journal-title":"Adv Ther"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/14786419.2018.1552698","volume":"34","author":"Shahzad Y.","year":"2020","unstructured":"Shahzad Y.; Maqbool M.; Hussain T.; Natural and semisynthetic polymers blended orodispersible films of citalopram. Nat Prod Res 2020,34(1),16-25","journal-title":"Nat Prod Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.1038\/srep08902","volume":"5","author":"Kucka M.","year":"2015","unstructured":"Kucka M.; Tomi\u0107 M, Bjelobaba I, Stojilkovic SS, Budimirovic DB. Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Sci Rep 2015,5(1),8902","journal-title":"Sci Rep"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527321666220301122807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/201534\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527321666220301122807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T07:42:32Z","timestamp":1676533352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/201534\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527321666220301122807","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}